March 5, 2020 / 7:42 PM / 24 days ago

BRIEF-Tg Therapeutics Receives Orphan Drug Designation For Umbralisib From The U.S. Food And Drug Administration

March 5 (Reuters) - TG Therapeutics Inc:

* TG THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FOR UMBRALISIB FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF FOLLICULAR LYMPHOMA

* TG THERAPEUTICS INC - LOOK FORWARD TO COMPLETION OF ROLLING SUBMISSION FOR UMBRALISIB IN MZL & FL TARGETED IN FIRST HALF OF THIS YEAR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below